Velocity Bio
Velocity Bio is a Stanford spinout developing a next-generation biophysical assay platform that delivers higher-scale, higher-quality data to help early drug discovery researchers transition from blind screening to targeted allosteric design.
- Company typePrivate
- Founded2023
- HeadquartersSan Carlos, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Velocity Bio firmographics
Firmographics- Name
- Velocity Bio
- Legal name
- Velocity Bio, Inc.
- Website
- https://www.velocitybio.tech/
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Velocity Bio is a Stanford spinout developing a next-generation biophysical assay platform that delivers higher-scale, higher-quality data to help early drug discovery researchers transition from blind screening to targeted allosteric design.
- Ownership category
- akta.pro rank
Velocity Bio industry classification
Industry- Product category
- Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)
- akta.pro secondary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where Velocity Bio is headquartered
LocationHeadquarters
- HQ city
- San Carlos
- HQ country
- United States
- HQ region
- North America
Markets served
Velocity Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Marketing channels2 records
Velocity Bio product offering
Product offeringCore offering
Velocity Bio develops and provides a next-generation biophysical assay platform aimed at early drug discovery. The platform delivers greater scale and quality of biophysical data than conventional screening approaches, enabling researchers to move from blind empirical screening to targeted molecular design, with a particular focus on selectivity-first allosteric drug discovery.
Differentiator
Problem solved
Functional benefit
Products and services
- Velocity Bio Platform The Velocity Bio Platform is a next-generation biophysical assay platform designed to deliver greater scale and quality of data for early drug discovery. It is built to enable the transition from traditional blind screening approaches to targeted design, with a particular focus on selectivity-first allosteric drug discovery. It serves pharmaceutical and biotechnology researchers who require richer biophysical data to support early-stage molecular design.
Companies that use Velocity Bio
Customer profileSegments1 record
Ideal customer profiles1 record
Velocity Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Velocity Bio partnerships and signals
Strategic signalScale indicators1 record
Velocity Bio competitors and assessment
Company assessmentDirect peers
- Exscientia: AI-driven drug discovery company with end-to-end platform spanning target ID to clinical candidate. Direct comparable for a platform-driven, data-led early-discovery business model.
- Schrödinger, Inc. Operates a computational drug discovery platform combining physics-based simulation with ML. Direct comparable as a platform business serving pharma discovery customers with biophysical / computational data.
- Recursion Pharmaceuticals: Techbio company using high-throughput, automated wet-lab biology and ML to discover drugs. Comparable as a platform play that sells or partners discovery capabilities to pharma with emphasis on data scale.
- Relay Therapeutics: Clinical-stage precision medicine company focused on allosteric drug discovery using a motion-based protein motion platform. Direct competitor in the allosteric / selectivity-first discovery space and the closest strategic comparable for Velocity Bio's positioning.
- HotSpot Therapeutics: Biotech developing small-molecule therapeutics that target naturally occurring regulatory sites on proteins — essentially allosteric drug discovery. Highly comparable in both scientific focus (allosteric / selectivity) and stage to Velocity Bio.
- Frontier Medicines: Precision medicine company using chemoproteomics and computational chemistry to discover allosteric and covalent modulators of hard-to-drug targets. Comparable in targeting allosteric / selectivity-first discovery workflows.
- SAMDI Tech: Label-free, high-throughput biochemical assay CRO built on SAMDI mass spectrometry for primary and secondary screening. Highly comparable in offering biophysical, label-free assay data for early drug discovery workflows.
- Carterra: Provider of high-throughput surface plasmon resonance (SPR) instruments and consumables for biomolecular interaction analysis. Comparable as a biophysical measurement / assay technology company serving drug discovery customers.
Broad incumbents
- Reaction Biology: CRO providing biophysical, biochemical, and cell-based assay services for drug discovery. Broad incumbent comparable in the biophysical assay / early-discovery services space.
- Eurofins Discovery: Large CRO offering broad drug discovery services including assay development, HTS, and biophysics. Broad incumbent comparable in delivering biophysical assay / discovery services to pharma customers.
Market position
Customer concentration
Velocity Bio social profiles
Digital presenceVelocity Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Velocity Bio leadership team
Management profileNumber of profiles
Profiles1 record
Velocity Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Velocity Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Velocity Bio
What does Velocity Bio do?
Velocity Bio develops and provides a next-generation biophysical assay platform aimed at early drug discovery. The platform delivers greater scale and quality of biophysical data than conventional screening approaches, enabling researchers to move from blind empirical screening to targeted molecular design, with a particular focus on selectivity-first allosteric drug discovery.
When was Velocity Bio founded?
Velocity Bio was founded in 2023. It employs 1 to 10 people.
Where is Velocity Bio based?
Velocity Bio is headquartered in San Carlos, United States, in the North America region.
Who are Velocity Bio's main competitors?
Direct peers on record are Exscientia, Schrödinger, Inc., Recursion Pharmaceuticals, Relay Therapeutics, HotSpot Therapeutics, Frontier Medicines, SAMDI Tech and Carterra. Broad incumbents are Reaction Biology and Eurofins Discovery.
Does Velocity Bio have an API?
No public API is recorded for Velocity Bio.
What industry is Velocity Bio in?
Velocity Bio's product category is Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.